CB2 Receptor Modulators for Antitumor Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving the cannabinoid receptor CB2, face challenges in enhancing antitumor immune responses due to immunosuppressive effects caused by endocannabinoids, leading to impaired T, NK, and B cell function.
Innovation Solution
Development of CB2 receptor modulators, including antagonists and inverse agonists, represented by specific compounds of Formula (I) and Formula (X), which modulate CB2 receptor activity to restore immune function and enhance antitumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If endocannabinoids are present to modulate immune responses, then anti-inflammatory effects are achieved, but immunosuppression occurs that impairs T, NK, and B cell function
Solution Approach 1:
The patent extracts and isolates the harmful immunosuppressive effect from the beneficial anti-inflammatory effect by selectively blocking CB2 receptors. This allows the immune system to maintain anti-inflammatory responses while preventing the suppression of T, NK, and B cell functions that occurs through CB2-mediated pathways.
Solution Approach 2:
The patent introduces CB2 receptor antagonists as intermediary substances that mediate between endocannabinoids and immune cells. These antagonists selectively interfere with the immunosuppressive signaling pathway while permitting other immune regulatory mechanisms to function normally, thus resolving the contradiction between inflammation control and immune responsiveness.
2Object-affected harmful factors
If CB2 receptor activity is enhanced to reduce inflammation, then anti-inflammatory response is improved, but antitumor immune response is suppressed
Solution Approach 1:
The patent applies inversion by switching from CB2 receptor agonists (which enhance anti-inflammatory effects but suppress immunity) to CB2 receptor antagonists. This inverse approach blocks the immunosuppressive signaling in the tumor microenvironment while still allowing control of inflammation through alternative pathways, thereby converting the harmful effect into a beneficial one for cancer therapy.
Solution Approach 2:
The patent applies local quality by developing antagonists that specifically target CB2 receptors in the tumor microenvironment and immune cells, rather than systemically suppressing all CB2-mediated effects. This localized blockade preserves anti-inflammatory responses in non-tumor tissues while eliminating immunosuppression where it matters most for cancer treatment.
3Reliability
If conventional cancer treatments are used, then tumor growth is controlled, but antitumor immune response is not enhanced due to CB2-mediated immunosuppression
Solution Approach 1:
The patent merges conventional cancer therapies with CB2 receptor antagonism into a combined treatment approach. By integrating the tumor control effects of conventional treatments with the immune-enhancing effects of CB2 blockade, the synergistic combination achieves both reliable tumor control and enhanced antitumor immune response, overcoming the limitations of either approach alone.
Data Source
AI summary
Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).